Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin

被引：0
|
作者：
Kristen DeCarlo
Amisha Wallia
Raymond H. Kang
Andrew Cooper
Manisha Cherupally
Sterling A. Harris
Cassandra Aikman
David T. Liss
Ronald T. Ackermann
Matthew J. O’Brien
机构：
[1] University of Illinois at Chicago,Division of Endocrinology, Diabetes and Metabolism, Department of Medicine
[2] Northwestern University Feinberg School of Medicine,Division of Endocrinology, Metabolism and Molecular Medicine, Department of Medicine
[3] Northwestern University Feinberg School of Medicine,Institute of Public Health and Medicine
[4] Northwestern University Feinberg School of Medicine,Division of General Internal Medicine and Geriatrics, Department of Medicine
来源：
BMC Geriatrics | / 22卷
关键词：
Type 2 diabetes; Older adults; Antidiabetic medications; Sulfonylureas; Insulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
    Zhu, Jiejin
    Zhou, Ying
    Li, Qingyu
    Wang, Gang
    ADVANCES IN THERAPY, 2023, 40 (10) : 4216 - 4235
  • [22] COMPARATIVE EFFECTIVENESS ON CARDIOVASCULAR OUTCOMES OF METFORMIN INITIAL THERAPY AND ADD-ON SECOND-LINE DRUGS AMONG PATIENTS WITH TYPE 2 DIABETES
    Kim, Y.
    Ko, M.
    Jo, A.
    Kang, S.
    Tchoe, H.
    Park, C.
    Kim, H.
    Choi, J.
    Park, D.
    Lee, W.
    VALUE IN HEALTH, 2015, 18 (07) : A382 - A382
  • [23] Trends in Timing of and Glycemia at Initiation of Second-line Type 2 Diabetes Treatment in US Adults
    Raghavan, Sridharan
    Warsavage, Theodore
    Liu, Wenhui G.
    Raffle, Katherine
    Josey, Kevin
    Saxon, David R.
    Phillips, Lawrence S.
    Caplan, Liron
    Reusch, Jane E. B.
    DIABETES CARE, 2022, 45 (06) : 1335 - 1345
  • [24] Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes
    Vashisht, Rohit
    Patel, Ayan
    Dahm, Lisa
    Han, Cora
    Medders, Kathryn E.
    Mowers, Robert
    Byington, Carrie L.
    Koliwad, Suneil K.
    Butte, Atul J.
    JAMA NETWORK OPEN, 2023, 6 (10) : E2336613
  • [25] Risk of hypoglycaemia associated with second-line agents in routine care patients with type 2 diabetes treated with metformin
    Pawar, A.
    Patorno, E.
    Lee, H.
    Munshi, M.
    Kim, D.
    DIABETOLOGIA, 2019, 62 : S411 - S411
  • [26] Changes in Treatment Satisfaction Over 3 Years in Patients With Type 2 Diabetes After Initiating Second-line Treatment
    Mita, Tomoya
    Katakami, Naoto
    Takahara, Mitsuyoshi
    Kawashima, Masaru
    Wada, Fumitaka
    Akiyama, Hiroki
    Morita, Naru
    Kidani, Yoko
    Yajima, Toshitaka
    Shimomura, Iichiro
    Watada, Hirotaka
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (09): : 2424 - 2432
  • [27] Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China
    Gu, Shuyan
    Deng, Jing
    Shi, Lizheng
    Mu, Yiming
    Dong, Hengjin
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (10) : 808 - 820
  • [28] Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin
    Klarenbach, Scott
    Cameron, Chris
    Singh, Sumeet
    Ur, Ehud
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2011, 183 (16) : E1213 - E1220
  • [29] Insulin for type 2 diabetes: choosing a second-line insulin regimen
    Barnett, A.
    Begg, A.
    Dyson, P.
    Feher, M.
    Hamilton, S.
    Munro, N.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (11) : 1647 - 1653
  • [30] Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD
    Yu, Margaret K.
    Kim, Sun H.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 11 (12): : 2104 - 2106
12345